A Phosphatase Holoenzyme Comprised of Shoc2/Sur8 and the Catalytic Subunit of PP1 Functions as an M-Ras Effector to Modulate Raf Activity

Cited by (215)

Items 201–215 of 215

1. The impact of the BmSur8 gene, encoding a scaffold protein, on cocoon silk yield in Bombyx mori
   Si Zhou, Ying Gu, Houming Dai, Xun Clare Zhou, Sheng Qin, Muwang Li, Xia Sun · 2025 · Journal of Economic Entomology
2. Molecular Genetics of RASopathies
   Marco Tartaglia, Bruce D. Gelb · 2024 · Encyclopedia of Life Sciences
3. The Double Life of Shading of Cell 2 (SHOC2): Guardian of Skin Homeostasis and Accomplice of RAS- ERK Signaling
   José M. Rojas · 2025 · Journal of Regenerative Medicine and Biology Research
4. In vitro reconstitutions suggest a general model for paradoxical activation of ARAF, BRAF, and CRAF by diverse RAF inhibitor types that does not rely on negative allostery
   Emre Tkacik, Dong Man Jang, Kayla Boxer, Byung Hak Ha, Michael J. Eck · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
5. Etude phénotypique des cellules endométriosiques profondes
   Mahaut Leconte · 2012 · theses.fr (ABES)
6. Unraveling the Impact of KRAS Accessory Proteins on Oncogenic Signaling Pathways
   Vanshika Garg, Raphael N. H. M. Hofmann, Moazzam Saleem, Amin Mirzaiebadizi, Ghazaleh sadat hashemi, Tooba Hameed, Bahareh Jooyeh, Silke Pudewell, Mehrnaz Mehrabipour, Niloufar Mosaddeghzadeh et al. · 2026 · Cells
7. In vitro reconstitutions suggest a general model for paradoxical activation of ARAF, BRAF, and CRAF by diverse RAF inhibitor types that does not rely on negative allostery
   Emre Tkacik, Dong Man Jang, Kayla Boxer, Byung Hak Ha, Michael J. Eck · 2026 · eLife
8. In vitro reconstitutions suggest a general model for paradoxical activation of ARAF, BRAF, and CRAF by diverse RAF inhibitor types that does not rely on negative allostery
   Emre Tkacik, Dong Man Jang, Kayla Boxer, Byung Hak Ha, Michael J. Eck · 2026 · eLife
9. Rôle des récepteurs des xénobiotiques CAR (Constitutive Androstane Receptor, NR1I3) et PXR (Pregnane X receptor, NR1I2) dans le métabolisme des chimiothérapies conventionnelles du cancer colorectal
   Géraldine Leguelinel · 2011
10. Rôle des kinases LAMMER et des phosphatases PTP1B/PTP61F dans la régulation des voies de signalisation médiées par l'insuline
    Stéphane Tchankouo Nguetcheu · 2012
11. Evolution of protein motifs in their structural context : from mining motif resources available to the prediction of phenotype-specific motifs
    Paul de Boissier · 2022
12. SHOC2 Is a Novel Cause of Central Conducting Lymphatic Anomaly
    Jessica C. Ding, Benjamin A Sempowski, Lola Zerbib, Gregory T. Adamson, Christine Insinna, Christopher M. Marshall, Sanjay Sinha, Audrey J. Breckenridge, Rachel R. Amedume, Jessica T. E. Johnson et al. · 2026 · American Journal of Medical Genetics Part A
13. SCRIB inhibits PP1 phosphatase activity without blocking or structurally altering its active site
    Siba Alharbi, Amit Kumawat, Brandon Huntington, Afaque A. Momin, Shaden Alfaiyz, Vincenzo Di Florio, Marta Rigoli, Kelly J. Cardona‐Londoño, Walter Rocchia, Anandsukeerthi Sandholu et al. · 2026 · Journal of Biological Chemistry
14. Molecular mechanism of KRAS binding to BRAF and its regulation by the BRAF-specific region
    Daniel A. Bonsor, Suzanne I. Sandin Lawrence, Timothy H. Tran, Monalisa Swain, Srisathiyanarayanan Dharmaiah, Jennifer L. Mehalko, Simon A. J. Messing, Dwight V. Nissley, Frank P. McCormick, Andrew G. Stephen et al. · 2026 · Structure
15. BindingDB Entry 50015760: The overview of Mitogen-activated extracellular signal-regulated kinase (MEK)-based dual inhibitor in the treatment of cancers.
    BindingDB · 2023 · UC San Diego